Every year, innovators across complex industries run pilots that produce results no one else can use. Different measurement frameworks, different population definitions, different ways of describing what changed. The insight stays local. Nothing compounds.
Capital flows on narrative and relationships, not validated patterns. Vendors claim full credit for outcomes that result from coordinated efforts. For corporates, this means innovation decisions carry unnecessary risk — there is no shared evidence base to draw on before committing.
Japan faces the world's most acute demographic challenge: the fastest-aging population, the highest cost pressures in care, and a corporate sector actively seeking validated innovation. The bathroom is the most data-rich, least monitored space in residential care — producing continuous passive signals that are the earliest detectable indicator of UTI, fluid imbalance, and hydration decline.
Founding partner TOTO brings smart bathroom hardware to the network. We are building in-house living labs and partnering with operators globally to generate the validated evidence that drives real decision-making benefits — for clinicians, care operators, and those building the next generation of care environments.
The Chorus methodology is designed to be sector-agnostic. Following healthspan, we are actively developing nodes across real estate, dual-use technologies, transport, mining, energy, and quantum computing — wherever complex innovation decisions require validated, comparable evidence rather than narrative.